Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New eczema drug ATTO-3712 enters early human safety trials

NCT ID NCT07205081

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called ATTO-3712 in healthy adults and people with atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored with clinic visits and symptom diaries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

48 people

The number who actually took part.

Started

Oct 2025

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 65 years old, inclusive, at Screening. * Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2 * Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs * Negative pregnancy test for participants of child-bearing potential. Part 3 (Participants with Atopic Dermatitis) Key Inclusion Criteria: * Any sex or gender who is 18 to 65 years old * Body weight of 50 to 125 kg and BMI between 18.5 and 40 kg/m2 * Clinically confirmed diagnosis of active AD * History of inadequate response to treatment with topical medications * Baseline weekly mean of daily PP-NRS ≥ 4 at Day 1. * EASI score of ≥ 16 at Screening and Day 1 * vIGA-AD score of ≥ 3 at Screening and Day 1 * ≥10% of body surface area (BSA) affected by AD at Screening and Day 1 * Use of topical bland emollient (moisturizer) at least once daily for at least 5 of the 7 days immediately before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study * Negative pregnancy test for participants of childbearing potential Parts 1 \& 2 (Healthy Volunteers) Key Exclusion Criteria * Any clinically significant underlying illness * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of uncontrolled asthma requiring rescue treatment with a bronchodilator for an increase in symptoms more than twice per week * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine) * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV * Active or latent tuberculosis infection * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day * History of drug or alcohol abuse * Laboratory values outside of the normal range Part 3 (Participants with Atopic Dermatitis) Key Exclusion Criteria: * Any clinically significant underlying illness * Presence of skin comorbidities that may interfere with study assessments * Has taken prescription medication for the treatment of AD or other prohibited medication within the restricted time limits (defined in the protocol) * Has applied topical corticosteroids within 2 weeks prior to dosing. * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of uncontrolled asthma requiring rescue treatment with a bronchodilator for an increase in symptoms more than twice per week * History of recurrent eczema herpeticum * History of known primary immunodeficiency, is considered immunocompromised, history of untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months * History of major depression * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine) * Participant has experienced significant flare(s) in AD in the 2 weeks prior to Screening or during the Screening period * EASI score for the participant has more than doubled between Screening and Day 1 * Active HBV or HCV or is positive for HIV * Participant is smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent to approximately 40 mg nicotine) per day * Participant has an ECG with a QTcF \> 450 msec for males or \> 470 msec for females at Screening * History of drug or alcohol abuse * Laboratory values outside of the normal range

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Altasciences

    Montreal, Quebec, H3P 3P1, Canada

  • Attovia Clinical Site 102

    Peterborough, Ontario, K9J 5K2, Canada

  • Attovia Clinical Site 202

    Saint Joseph, Missouri, 64506, United States

  • Attovia Clinical Site 203

    Encinitas, California, 92024, United States

  • Attovia Clinical Site 204

    Rocklin, California, 95765, United States

  • Attovia Clinical Site 205

    Huntington Beach, California, 92647, United States

  • Attovia Clinical Site 206

    Indianapolis, Indiana, 46250, United States

  • Attovia Clinical Site 207

    Sweetwater, Florida, 33172, United States

  • Attovia Clinical Site 208

    Coral Gables, Florida, 33134, United States

  • Attovia Clinical Site 209

    Fountain Valley, California, 92708, United States

  • Attovia Clinical Site 210

    New York, New York, 10128, United States

  • Attovia Clinical Site 301

    Auckland, Auckland, 1010, New Zealand

  • Attovia Clinical Site 302

    Hamilton, NZ, 3204, New Zealand

  • Attovia Clinical Site 303

    Nelson, NZ, 7011, New Zealand

  • Attovia Clinical Site 304

    Christchurch, NZ, 8000, New Zealand

  • Attovia Clinical Site 305

    Wellington, NZ, 6021, New Zealand

  • Attovia Clinical Site 306

    Auckland, NZ, 0626, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.